Company Filing History:
6 out of 15 
1 out of 2 
1 out of 1,500 
Years Active: 2006-2019
Title: **Olle Korsgren: Innovator in Therapeutic Cell Transplantation**
Introduction
Olle Korsgren, an esteemed inventor based in Uppsala, Sweden, has made significant contributions to the field of medical innovations. With a remarkable portfolio of nine patents, Korsgren's work focuses on advancing therapeutic techniques for transplantation and cancer treatment.
Latest Patents
Among his latest patents is the "Use of dextran sulfate," which outlines a graft composition intended for transplantation into human patients. This innovative approach incorporates an injection solution that combines an isolated therapeutic cell transplant with dextran sulfate, or its pharmaceutically acceptable salts, boasting an average molecular weight of less than 20,000 Da. Another notable patent, "Methods for reducing pulmonary uptake of intravenously injected cells," highlights how dextran sulfate can effectively mitigate the pulmonary uptake of injected cells. This method achieves levels comparable to intra-arterial cell injection while avoiding its associated risks and side effects. Such advancements hold promise for enhancing treatments involving tumor-infiltrating T-lymphocytes in metastatic cancer.
Career Highlights
Throughout his career, Olle Korsgren has been affiliated with prominent companies such as Tx Medic AB and Tikomed AB. His role in these organizations has facilitated the application of his inventive research in practical and impactful solutions in the medical field.
Collaborations
Korsgren has collaborated with notable professionals in his field, including Bo Nilsson and Adam Bruce. These partnerships have not only enriched his work but have also contributed to the advancement of therapeutic methodologies within the context of transplantation and cancer treatment.
Conclusion
Olle Korsgren's innovative contributions illustrate a deep commitment to improving healthcare through technological advancements. His patents are a testament to his dedication to developing groundbreaking solutions that hold the potential to transform therapeutic practices for patients worldwide.